HOUSTON, Nov. 8, 2018 /PRNewswire/ -- Marker
Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology
company, today announced that its President and CEO, Peter L. Hoang, will participate in three
upcoming healthcare conferences. Mr. Hoang will participate in a
panel discussion titled "Drug Pricing and Development Challenges"
at the CEO Life Sciences and Pharmaceuticals Symposium on
November 13, 2018 in New York City, and will give corporate
overviews at the Piper Jaffray 30th Annual Healthcare
Conference on November 27, 2018 in
New York City and at the Evercore
ISI HealthconX Conference on November 28,
2018 in Boston.
CEO Life Sciences and Pharmaceuticals
Symposium
Title: Drug Pricing and Development
Challenges
Date: Tuesday, November 13,
2018
Time: 5:00pm – 6:30pm (EST)
Location: Yellow Room, 107 East 16th Street,
New York City
Piper Jaffray 30th Annual Healthcare
Conference
Date: Tuesday,
November 27, 2018
Time: 12:00pm – 12:25pm (EST)
Location: Lotte New York Palace, Holmes 1, 4th Floor
Evercore ISI HealthconX Conference
Date:
Wednesday, November 28, 2018
Time: 10:35am – 10:55am (EST)
Location: Boston Harbor Hotel, South Atlantic Room,
2nd Floor
Webcasts for the Piper Jaffray and Evercore ISI conferences will
be made available at https://markertherapeutics.com/events/
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. Once infused into patients,
this population of T cells attacks multiple tumor targets and acts
to activate the patient's immune system to produce broad spectrum
anti-tumor activity. Because Marker does not genetically engineer
its T cells, when compared to current engineered CAR-T and
TCR-based approaches, its products (i) are significantly less
expensive and easier to manufacture, (ii) appear to be markedly
less toxic, and (iii) are associated with meaningful clinical
benefit. As a result, Marker believes its portfolio of T cell
therapies has a compelling therapeutic product profile, as compared
to current gene-modified CAR-T and TCR-based therapies.
Marker is also advancing several innovative peptide- and
gene-based immuno-therapeutics for the treatment of cancer and
metastatic disease, including our Folate Receptor Alpha program
(TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide
antigen program (TPIV100/110) in Phase II clinical trials. In
parallel, we are developing a proprietary DNA expression technology
named PolyStart™ to improve the ability of the cellular immune
system to recognize and destroy diseased cells.
For additional information, please call toll free at (904)
862-6490 or visit: markertherapeutics.com
To receive future press releases via email, please visit:
https://markertherapeutics.com/email-alerts/
Follow us on Twitter @MRKRTherapeutic, or follow us on
Facebook.
Forward-Looking Statement Disclaimer
This release
contains forward-looking information within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements in
this news release concerning the Company's expectations, plans,
business outlook or future performance, and any other statements
concerning assumptions made or expectations as to any future
events, conditions, performance or other matters, are
"forward-looking statements". Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things:
our research and development activities relating to our
multi-antigen specific T cell therapies; our TPIV200 and
TPIV100/110 programs and our PolyStart™ program; the
effectiveness of these programs or the possible range of
application and potential curative effects and safety in the
treatment of diseases; and, the timing and success of our clinical
trials. Forward-looking statements are by their nature subject to
risks, uncertainties and other factors which could cause actual
results to differ materially from those stored in such statements.
Such risks, uncertainties and factors include, but are not limited
to the risks set forth in the Company's most recent Form 10-K, 10-Q
and other SEC filings which are available through EDGAR at
www.sec.gov. The Company assumes no obligation to update the
forward-looking statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-three-upcoming-healthcare-conferences-300746350.html
SOURCE Marker Therapeutics, Inc.